Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice

Prostate

Volumn 73, Issue 14, 2013, Pages 1507-1517

  Shukla, Sanjeev ^a   Bhaskaran, Natarajan ^a   Maclennan, Gregory T ^a   Gupta, Sanjay ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cell cycle; forkhead transcription factors; PI3K Akt; prostate cancer; PTEN; TRAMP

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION;

CELL CYCLE; FORKHEAD TRANSCRIPTION FACTORS; PI3K/AKT; PROSTATE CANCER; PTEN; TRAMP;

ADENOCARCINOMA; ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84883137971     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22698     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E,. Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 2012; 62: 220-241.
3. Schoenfield L, Jones JS, Zippe CD, Reuther AM, Klein E, Zhou M, Magi-Galluzzi C,. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int 2007; 99: 770-774.
4. Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M,. Cancer genetics and genomics of human FOX family genes. Cancer Lett 2013; 328: 198-206.
5. Zhang Y, Gan B, Liu D, Paik JH,. FoxO family members in cancer. Cancer Biol Ther 2011; 12: 253-259.
6. Seoane J, Le HV, Shen L, Anderson SA, Massagué J,. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117: 211-223.
7. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, Delattre O, Delorenzi M, Shipley J,. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30: 1670-1677.
8. Jagani Z, Singh A, Khosravi-Far R,. FoxO tumor suppressors and BCR-ABL-induced leukemia: A matter of evasion of apoptosis. Biochim Biophys Acta 2008; 1785: 63-84.
9. Wang L, Brugge JS, Janes KA,. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 2011; 108: E803-E812.
10. Zaballos MA, Santisteban P,. FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesis. Mol Endocrinol 2013; 27: 50-62.
11. Kim JH, Kim MK, Lee HE, Cho SJ, Cho YJ, Lee BL, Lee HS, Nam SY, Lee JS, Kim WH,. Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer. Mod Pathol 2007; 20: 835-842.
12. Mikse OR, Blake DC Jr, Jones NR, Sun YW, Amin S, Gallagher CJ, Lazarus P, Weisz J, Herzog CR,. FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma. Cancer Res 2010; 70: 6205-6215.
13. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP,. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441: 523-527.
14. Zhang X, Tang N, Hadden TJ, Rishi AK,. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813: 1978-1986.
15. Zhao Y, Wang Y, Zhu WG,. Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol 2011; 3: 276-282.
16. Tzivion G, Dobson M, Ramakrishnan G,. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011; 1813: 1938-1945.
17. Daitoku H, Sakamaki J, Fukamizu A,. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011; 1813: 1954-1960.
18. Ali IU, Schriml LM, Dean M,. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-1932.
19. Shen MM, Abate-Shen C,. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007; 67: 6535-6538.
20. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H,. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
21. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S,. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007; 121: 1424-1432.
22. Li R, Erdamar S, Dai H, Wheeler TM, Frolov A, Scardino PT, Thompson TC, Ayala GE,. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol 2007; 38: 1501-1507.
23. Shukla S, Shukla M, Maclennan GT, Fu P, Gupta S,. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol 2009; 34: 1613-1620.
24. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W, Dong JT,. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 2006; 66: 6998-7006.
25. Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL, Graff JR,. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 2005; 3: 163-169.
26. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM,. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55: 219-237.
27. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM,. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-4102.
28. Bethel CR, Bieberich CJ,. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Prostate 2007; 67: 1740-1750.
29. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S,. Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005; 64: 224-239.
30. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, Gupta S,. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 2007; 67: 6925-6935.
31. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA,. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309-323.
32. Abdulkadir SA, Kim J,. Genetically engineered murine models of prostate cancer: Insights into mechanisms of tumorigenesis and potential utility. Future Oncol 2005; 1: 351-360.
33. Ahmad I, Sansom OJ, Leung HY,. Advances in mouse models of prostate cancer. Expert Rev Mol Med 2008; 10: e16.
34. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M,. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001; 98: 11563-11568.